PIM2 Proto-Oncogene, Serine/Threonine Kinase
A key regulator of cell survival, proliferation, and hematological malignancies
Gene Information Card
| Symbol | PIM2 |
|---|---|
| Full Name | Pim-2 proto-oncogene, serine/threonine kinase |
| Gene Type | protein-coding |
| Chromosomal Location | Xp11.23 |
| NCBI Gene ID | 11040 ncbi.nlm.nih.gov/gene/11040 |
| Ensembl ID | ENSG00000102096 |
| UniProt ID | Q9P1W9 |
| OMIM ID | 300295 |
| HGNC ID | 8987 |
| Aliases | PIM2H, PIM2L |
Description
PIM2 encodes a serine/threonine kinase that belongs to the PIM family of proto-oncogenes. The protein is involved in cell cycle progression, apoptosis inhibition, and regulation of transcription and translation. It is frequently overexpressed in hematological malignancies and is considered a therapeutic target.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Multiple myeloma | Overexpression of PIM2 promotes cell survival and resistance to apoptosis via phosphorylation of BAD and 4E-BP1 | PMID: 16912224; COSMIC |
| Diffuse large B-cell lymphoma | PIM2 is upregulated and contributes to proliferation and survival through STAT3/5 signaling | PMID: 23341540; COSMIC |
| Acute myeloid leukemia | PIM2 expression is elevated and associated with poor prognosis; kinase activity supports leukemic cell growth | PMID: 25205116; COSMIC |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Bone marrow | 12.5 | Medium |
| Lymph node | 10.8 | Medium |
| Spleen | 9.2 | Medium |
| Thymus | 7.1 | Low |
| Peripheral blood leukocytes | 6.3 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| K-562 (chronic myeloid leukemia) | 15.2 | High expression |
| Raji (Burkitt lymphoma) | 12.8 | High expression |
| MOLT-4 (T-cell leukemia) | 10.5 | Medium expression |
| HL-60 (acute promyelocytic leukemia) | 9.1 | Medium expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.331C>T (p.Arg111Trp) | Missense | <1% | Unknown functional effect; reported in COSMIC |
| c.487G>A (p.Gly163Arg) | Missense | <1% | Unknown functional effect; reported in COSMIC |
| c.614A>G (p.Asn205Ser) | Missense | <1% | Unknown functional effect; reported in COSMIC |
Mutation functional classification
Loss of Function (LOF)
No confirmed loss-of-function mutations reported in COSMIC or ClinVar.
Gain of Function (GOF)
No confirmed gain-of-function mutations reported; overexpression is the primary oncogenic mechanism.
Dominant Negative (DN)
No dominant-negative mutations described.
View complete mutation data：
Gene Ontology (GO)
Pathways
• PI3K/Akt signaling (Reactome: R-HSA-1257604)
• JAK/STAT signaling (Reactome: R-HSA-8950505)
• mTOR signaling (Reactome: R-HSA-165159)
• Apoptosis modulation (Reactome: R-HSA-109581)
Protein Summary
PIM2 is a 34 kDa serine/threonine kinase with a short half-life. It phosphorylates substrates such as BAD, 4E-BP1, and MYC to promote cell survival and protein translation. The kinase domain is highly conserved among PIM family members. PIM2 lacks a regulatory domain and is constitutively active when expressed. It is predominantly cytoplasmic but can shuttle to the nucleus.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PIM2 Knockout HEK293 Cell Line | EDJ-KQ2068 | Human | 11040 | Details Get a Quote |
| PIM2 Knockout A-549 Cell Line | EDJ-KQ22136 | Human | 11040 | Details Get a Quote |
| PIM2 Knockout HCT 116 Cell Line | EDJ-KQ22137 | Human | 11040 | Details Get a Quote |
| PIM2 Knockout HeLa Cell Line | EDJ-KQ22138 | Human | 11040 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
